Skeletal aging and the adipocyte program: New insights from an "old" molecule

Cell Cycle

Volumn 9, Issue 18, 2010, Pages 3672-3678

  Lecka Czernik, Beata ^a   Rosen, Clifford J ^b   Kawai, Masanobu ^b  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

Aging; Bone; IGF I; Nocturnin; PPAR

Indexed keywords

COLONY STIMULATING FACTOR 1; NOCTURNIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADIPOCYTE; BONE DEVELOPMENT; BONE MARROW; BONE MASS; CELL AGING; CELL FATE; GENE OVEREXPRESSION; HUMAN; MOLECULAR MECHANICS; NONHUMAN; OSTEOLYSIS; PROTEIN EXPRESSION; REVIEW; STEM CELL; STROMA CELL;

EID: 77956985003     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.18.13046     Document Type: Review

References (69)

1. Rosen CJ. Bone remodeling, energy metabolism and the molecular clock. Cell Metab 2008; 7:7-10.
2. Ackert-Bicknell CL, Shockley KR, Horton LG, Lecka-Czernik B, Churchill GA, Rosen CJ. Strain-specific effects of rosiglitazone on bone mass, body composition and serum insulin-like growth factor-I. Endocrinology 2009; 150:1330-40.
3. Kawai M, Sousa KM, Macdougald OA, Rosen CJ. The Many Facets of PPAR{gamma}: Novel Insights for the Skeleton. Am J Physiol Endocrinol Metab 2010; 299:3-9.
4. Yadav VK, Karsenty G. Leptin-dependent co-regulation of bone and energy metabolism. Aging 2009; 5:954-6.
5. Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop Relat Res 1971; 80:147-54.
6. Shockley KR, Lazarenko OP, Czernik PJ, Rosen CJ, Churchill GA, Lecka-Czernik B. PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem 2009; 106:232-46.
7. Lecka-Czernik B. PPARs in bone: the role in bone cell differentiation and regulation of energy metabolism. Curr Osteoporos Rep 2010; 8:84-90.
8. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006; 7:885-96.
9. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008; 77:289-312.
10. Moerman EJ, Teng K, Lipschitz DA, Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGFbeta/BMP signaling pathways. Aging Cell 2004; 3:379-89.
11. Lecka-Czernik B. Bone as a target of type 2 diabetes treatment. Curr Opin Investig Drugs 2009; 10:1085-90.
12. Kawai M, Green CB, Horowitz M, Ackert-Bicknell C, Lecka-Czernik B, Rosen CJ. Nocturnin: a circadian target of Pparg-induced adipogenesis. Ann N Y Acad Sci 2010; 1192:131-8.
13. Kawai M, Green CB, Lecka-Czernik B, Douris N, Gilbert MR, Kojima S, et al. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-{gamma} nuclear translocation. Proc Natl Acad Sci USA 2010; 107:10508-13.
14. Green CB, Douris N, Kojima S, Strayer CA, Fogerty J, Lourim D, et al. Loss of Nocturnin, a circadian deadenylase, confers resistance to hepatic steatosis and diet-induced obesity. Proc Natl Acad Sci USA 2007; 104:9888-93. (Pubitemid 47175361)
15. Manolagas SC. Cellular and molecular mechanisms of osteoporosis. Aging (Milano) 1998; 10:182-90.
16. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010; 31:266-300.
17. Scicchitano BM, Rizzuto E, Musarò A. Counteracting muscle wasting in aging and neuromuscular diseases: the critical role of IGF-1. Aging 2009; 13:451-7.
18. Botolin S, McCabe LR. Bone loss and increased bone adiposity in spontaneous and pharmacologically induced diabetic mice. Endocrinology 2007; 148:198-205. (Pubitemid 46021451)
19. Gimble JM, Robinson CE, Wu X, Kelly KA, Rodriguez BR, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996; 50:1087-94. (Pubitemid 26384846)
20. Naveiras O, Nardi V, Wenzel PL, Hauschka PV, Fahey F, Daley GQ. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature 2009; 460:259-63.
21. Cartwright MJ, Tchkonia T, Kirkland JL. Aging in adipocytes: potential impact of inherent, depot-specific mechanisms. Exp Gerontol 2007; 42:463-71. (Pubitemid 46756096)
22. Gasparrini M, Rivas D, Elbaz A, Duque G. Differential expression of cytokines in subcutaneous and marrow fat of aging C57BL/6J mice. Exp Gerontol 2009; 44:613-8.
23. Elefteriou F, Ahn JD, Takeda S, Starbuck M, Yang X, Liu X, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 2005; 434:514-20.
24. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002; 111:305-17. (Pubitemid 35345151)
25. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol 2002; 175:405-15.
26. Hamrick MW, Pennington C, Newton D, Xie D, Isales C. Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone 2004; 34:376-83.
27. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006; 99:196-208.
28. Oshima K, Nampei A, Matsuda M, Iwaki M, Fukuhara A, Hashimoto J, et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun 2005; 331:520-6.
29. Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol 2009; 5:365-72.
30. Sheng MH, Baylink DJ, Beamer WG, Donahue LR, Rosen CJ, Lau KH, et al. Histomorphometric studies show that bone formation and bone mineral apposition rates are greater in C3H/HeJ (high-density) than C57BL/6J (low-density) mice during growth. Bone 1999; 25:421-9.
31. Rosen CJ, Ackert-Bicknell CL, Adamo ML, Shultz KL, Rubin J, Donahue LR, et al. Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density and an altered osteoblast differentiation program. Bone 2004; 35:1046-58.
32. Lecka-Czernik B, Suva LJ. Resolving the Two "Bony" Faces of PPAR-gamma. PPAR Res 2006; 27489.
33. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation and cell growth. J Biol Chem 2001; 276:37731-4.
34. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung UI, Kubota N, et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004; 113:846-55.
35. Cock TA, Back J, Elefteriou F, Karsenty G, Kastner P, Chan S, et al. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004; 5:1007-12. (Pubitemid 39534460)
36. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009; 66:236-53.
37. Lecka-Czernik B, Gubrij I, Moerman EJ, Kajkenova O, Lipschitz DA, Manolagas SC, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999; 74:357-71. (Pubitemid 29344887)
38. Wagner W, Bork S, Lepperdinger G, Joussen S, Ma N, Strunk D, et al. How to track cellular aging of mesenchymal stromal cells? Aging 2010; 2:224-30.
39. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 2007; 13:1496-503.
40. Wei W, Wang X, Yang M, Smith LC, Dechow PC, Wan Y, et al. PGC1beta mediates PPARgamma activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 2010; 11:503-16.
41. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int 2004; 75:329-37. (Pubitemid 40064235)
42. Li M, Pan LC, Simmons HA, Li Y, Healy DR, Robinson BS, et al. Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone 2006; 39:796-806. (Pubitemid 44311719)
43. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology 2007; 148:2669-80.
44. Green CB, Takahashi JS, Bass J. The meter of metabolism. Cell 2008; 134:728-42.
45. Yang X, Downes M, Yu RT, Bookout AL, He W, Straume M, et al. Nuclear receptor expression links the circadian clock to metabolism. Cell 2006; 126:801-10. (Pubitemid 44233631)
46. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10:355-61.
47. Green CB, Besharse JC. Identification of a novel vertebrate circadian clock-regulated gene encoding the protein nocturnin. Proc Natl Acad Sci USA 1996; 93:14884-8.
48. Wang Y, Osterbur DL, Megaw PL, Tosini G, Fukuhara C, Green CB, et al. Rhythmic expression of Nocturnin mRNA in multiple tissues of the mouse. BMC Dev Biol 2001; 1:9.
49. Garbarino-Pico E, Niu S, Rollag MD, Strayer CA, Besharse JC, Green CB. Immediate early response of the circadian polyA ribonuclease nocturnin to two extracellular stimuli. Rna 2007; 13:745-55.
50. Baggs JE, Green CB. Nocturnin, a deadenylase in Xenopus laevis retina: a mechanism for posttranscriptional control of circadian-related mRNA. Curr Biol 2003; 13:189-98.
51. Dupressoir A, Morel AP, Barbot W, Loireau MP, Corbo L, Heidmann T. Identification of four families of yCCR4- and Mg2+-dependent endonuclease-related proteins in higher eukaryotes and characterization of orthologs of yCCR4 with a conserved leucine-rich repeat essential for hCAF1/hPOP2 binding. BMC Genomics 2001; 2:9.
52. Tucker M, Valencia-Sanchez MA, Staples RR, Chen J, Denis CL, Parker R. The transcription factor associated Ccr4 and Caf1 proteins are components of the major cytoplasmic mRNA deadenylase in Saccharomyces cerevisiae. Cell 2001; 104:377-86.
53. Kawai M, Rosen CJ. The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem 2010; [Epub ahead of print].
54. Kawai M, Rosen CJ. Insulin-like growth factor-I and bone: lessons from mice and men. Pediatr Nephrol 2009; 24:1277-85.
55. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96:7324-9.
56. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, et al. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110:771-81.
57. Javaid MK, Godfrey KM, Taylor P, Shore SR, Breier B, Arden NK, et al. Umbilical venous IGF-1 concentration, neonatal bone mass and body composition. J Bone Miner Res 2004; 19:56-63. (Pubitemid 41295138)
58. Garnero P, Sornay-Rendu E, Delmas PD. Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 2000; 355:898-9. (Pubitemid 30137673)
59. Langlois JA, Rosen CJ, Visser M, Hannan MT, Harris T, Wilson PW, et al. Association between insulin-like growth factor I and bone mineral density in older women and men: the Framingham Heart Study. J Clin Endocrinol Metab 1998; 83:4257-62.
60. Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology 2000; 141:2674-82.
61. Zhang M, Xuan S, Bouxsein ML, von Stechow D, Akeno N, Faugere MC, et al. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem 2002; 277:44005-12.
62. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, Marmolejos V, Churchill GA, Shockley KR, et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007; 148:903-110.
63. Goldstrohm AC, Wickens M. Multifunctional deadenylase complexes diversify mRNA control. Nat Rev Mol Cell Biol 2008; 9:337-44. (Pubitemid 351430850)
64. Foyt HL, LeRoith D, Roberts CT Jr. Differential association of insulin-like growth factor I mRNA variants with polysomes in vivo. J Biol Chem 1991; 266:7300-5. (Pubitemid 21906366)
65. Lund PK, Moats-Staats BM, Hynes MA, Simmons JG, Jansen M, D'Ercole AJ, et al. Somatomedin-C/insulin-like growth factor-I and insulin-like growth factor-II mRNAs in rat fetal and adult tissues. J Biol Chem 1986; 261:14539-44.
66. Delany AM, Canalis E. Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology 1995; 136:4776-81.
67. Kawai M, Delany AM, Green CB, Adamo ML, Rosen CJ. Nocturnin suppresses Igf1 expression in bone by targeting the 3' untranslated region of Igf1 mRNA. Endocrinology 2010; In press.
68. Cao SX, Dhahbi JM, Mote PL, Spindler SR. Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice. Proc Natl Acad Sci USA 2001; 98:10630-5.
69. Massiera F, Barbry P, Guesnet P, Joly A, Luquet S, Moreilhon Brest C, et al. A western-like fat diet is sufficient to induce a gradual enhancement in fat mass over generations. J Lipid Res 2010; 51:2352-2361.